alexa The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Bioequivalence & Bioavailability

Author(s): Larsson G, Milsom I, Lindstedt G, Rybo G

Abstract Share this page

Abstract The influence of a low-dose combined oral contraceptive (ethinyl estradiol 30 micrograms + desogestrel 0.15 mg) on menstrual blood loss (MBL) was evaluated in 20 healthy, young women. MBL prior to commencing oral contraception was 60.2 +/- 5.6 ml (range 22-116 ml), and decreased (p < 0.001) to 36.5 +/- 5.2 ml (range 7-80 ml) and 33.7 +/- 4.1 ml (range 5-70 ml) after 3 and 6 months' oral contraceptive medication, respectively. The reduction in MBL during oral contraception was most apparent during the first two days of menstruation. Five women had an MBL > 80 ml prior to commencing oral contraceptive medication. In all of these women, MBL during the 6th menstrual period after commencing oral contraception was < 80 ml. All the women included in this study had a normal blood hemoglobin concentration, hematocrit and erythrocyte indices and there were no significant changes in these variables during the course of the study. Serum ferritin concentration prior to commencing oral contraception was 44.2 +/- 9.0 micrograms/l and was largely unchanged after 6 months' oral contraception (39.7 +/- 6.3 micrograms/l). On admission to the study, two women had a serum ferritin < 10 micrograms/l, indicative of low iron stores. Both these women had an MBL > 80 ml at the baseline assessment. Serum ferritin concentration increased during oral contraceptive medication in both women (from 8.5 micrograms/l to 12.0 micrograms/l and from 5.4 micrograms/l to 6.8 micrograms/l, respectively). The duration of menstruation (p < 0.01) and the number of women suffering from dysmenorrhea (p < 0.05) was reduced during oral contraception. PIP: The influence of a low-dose combined oral contraceptive (OC) (ethinyl estradiol 30 mcg + desogestrel 0.15 mg) on menstrual blood loss (MBL) was evaluated in 20 healthy, young women. MBL prior to commencing OCs was 60.2 +or- 5.6 ml (range 22-116 ml), and decreased (p 0.001) to 36.5 +or- 5.2 ml (range 7-80 ml) and 33.7 +or- 4.1 ml (range 5-70 ml) after 3 and 6 months OC medication, respectively. The reduction in MBL during OC use was most apparent during the first 2 days of menstruation. 5 women had a MBL 80 ml prior to commencing OC medication. In all of these women, MBL during the 6th menstrual period after commencing OCs was 80 ml. All the women included in this study had a normal blood hemoglobin concentration, hematocrit, and erythrocyte indices and there were no significant changes in these variables during the course of the study. Serum ferritin concentration prior to commencing OCs was 44.2 +or- 9.0 mcg/l and was largely unchanged after 6 months' OCs (39.7 +or- 6.3 mcg/l). On admission to the study, 2 women had a serum ferritin level of 10 mcg/l, indicative of low iron stores. Both these women had a MBL of 80 ml at the baseline assessment. Serum ferritin concentration increased during OC medication in both women (from 8.5 mcg/l to 12.0 mcg/l and from 5.4 mcg/l to 6.8 mcg/l, respectively). The duration of menstruation (p 0.01) and the number of women suffering from dysmenorrhea (p 0.05) was reduced during OC use.
This article was published in Contraception and referenced in Journal of Bioequivalence & Bioavailability

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords